---
title: "This Psychedelics Stock Just Keeps Getting Hotter; Why Shares Bypassed A Profit-Taking Zone"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286791277.md"
description: "Compass Pathways experienced a significant surge on Monday due to increasing excitement surrounding the company's use of psilocybin in treating treatment-resistant depression. The stock continued to rise in value, bypassing a zone where investors typically take profits. This growing enthusiasm reflects the confidence in Compass Pathways' approach within the market."
datetime: "2026-05-18T14:47:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286791277.md)
  - [en](https://longbridge.com/en/news/286791277.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286791277.md)
---

# This Psychedelics Stock Just Keeps Getting Hotter; Why Shares Bypassed A Profit-Taking Zone

Compass Pathways experienced a significant surge on Monday due to increasing excitement surrounding the company's use of psilocybin in treating treatment-resistant depression. The stock continued to rise in value, bypassing a zone where investors typically take profits. This growing enthusiasm reflects the confidence in Compass Pathways' approach within the market.

### Related Stocks

- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)

## Related News & Research

- [H.C. Wainwright Sticks to Their Buy Rating for COMPASS Pathways (CMPS)](https://longbridge.com/en/news/286590906.md)
- [UK's Compass Pathways Q1 operating income beats estimates as expenses fall](https://longbridge.com/en/news/286243475.md)
- [Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights | CMPS Stock News](https://longbridge.com/en/news/286244376.md)
- [Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins](https://longbridge.com/en/news/287164867.md)
- [Fed Delay Fuels Yield Surge as Inflation Risks Persist](https://longbridge.com/en/news/287177279.md)